Schizophrenia is a psychiatric disorder, with distinct phenotypic features, that is still diagnosed based on characteristic clinical manifestations (DSM-IV-TR, with the new DSM-V draft to be finalized in 2013); there are no relevant fully validated biomarkers or laboratory-based tests (Kapur et al., 2012) . It is also currently viewed as a disorder of developmental origin, typically appearing in young adulthood.
Our understanding of the full range of alterations in brain structure and function that occur during the genesis of this disorder and how they can be modified by both genetic make-up and internal and external environmental context is just beginning to take off. Genetic studies, in particular, are fast providing new clues to the underlying biological changes that contribute to risk for developing/unmasking the relevant clinical phenotypes. There is evidence to make the case that the disease course is determined by a given individual's unique developmental trajectory-from conception through adulthood, across the aging spectrum. Because of this complex interplay, pinpointing key "tipping points" that define the neurobiological changes that drive the development of and maintain the schizophrenic phenotype remains a major challenge (Insel, 2010) .
We open this issue with three papers that alert us to specific environmental factors that seem to play key roles in unmasking vulnerabilities in different phases of life. First, Hamlyn et al. ask the question, from an epidemiologic point of view, whether there are modifiable non-genetic risk factors that impact early brain development. The authors chose to focus on non-genetic risk factors shared by both schizophrenia and autism since these disorders share common genetic risk factors. Through literature survey, advanced paternal age, pregnancy and birth complications, and migrant status, appear as identifiable additional shared risk factors (Hamlyn et al., 2013-this issue) . Second, Saito et al. review studies that support the contention that cannabis use in adolescence is a major risk factor for schizophrenia. During adolescence, the brain goes through dramatic changes, which include myelination and synaptic pruning. The endocannabinoid system plays crucial roles in more than one of these processes. In this article, the role of the endocannabinoid system, especially the cannabinoid receptor type 1 mediated signaling cascade, is detailed from both basic and clinical science points of view (Saito et al., 2013-this issue) . Following these two articles, Harvey et al. examine epidemiologic evidence from the other end of the spectrum. Although developmental in origin, schizophrenia currently evolves into a chronic disorder with life-long consequences mediated by declining cognitive function and variable impact on activities of daily living (Robinson et al., 2004) . It has long been suggested that chronic institutionalization further negatively impacts the disease course-a perception that led in large part in the 1970's to the widespread closing of the locked mental health wards and institution of community-based treatment programs. Disentangling the particular clinical and biologic features that are determinants of long hospitalization from the effects of hospitalization and medication is no easy task, but Harvey et al. tackle this issue (Harvey et al., 2013-this issue) .
We then shift attention to what is happening inside the brain. Each of the next three papers focuses on a different set of anatomic constructs relevant to the study of schizophrenia. Seshadri et al. have focused specific alterations in circuit-based synapses (Seshadri et al., 2013- 
this issue). Inan et al. review the role of cortical interneurons in the pathology of schizophrenia (Inan et al., 2013-this issue).
Takahashi and Sakurai (2013-this issue) play a framework for thinking about how disruption of nerve connectivity and inflammation as a result of glial cell dysfunction may contribute to the pathophysiology of the disorder. In the last article, Mouri et al. review available animal models that may be useful to study neurobiology of schizophrenia (Mouri et al., 2013-this issue) . The animal modeling repertoire for this disorder now includes a variety of chemical, genetic, environmental and other manipulations that alter function in specific brain regions/circuits. The range of models with reasonable face validity (the ability to recapitulate one or more core phenotypic features of the human disease) has increased significantly, although we need to pay attention to pitfalls in linking between mouse and human behaviors (Young et al., 2010) . Testing environmental/behavioral strategies for ameliorating specific behavioral phenotypes is now possible. Genetic manipulations may allow us to explore specific hypotheses of direct relevance to the molecular bases for the disorder.
In total, the articles in this issue underscore the acute need for continuing to ferret out links between the underlying genetics, developmental windows when the environmental milieu is particularly influential, the principles underlying the brain's adaptive repertoire in terms of metabolism, structure and function, and an individual patient's natural clinical course. In addition, as the reader will appreciate, it is increasingly apparent that the clinical moniker likely encompasses a spectrum of disorders now grouped under the same set of clinical definitions, but which will eventually be redefined based on specific underlying pathophysiology.
How quickly are we moving forward in our mission to help patients? The drug development pipeline already contains molecules that have a reasonable chance of fulfilling one or more of the most urgent unmet needs in treating schizophrenia: an anti-psychotic that works well but with a least side effect profile, drugs that improve negative symptoms, and medications that improve cognitive function. However, if we ask ourselves -"can we accurately predict who is at risk for developing schizophrenia?", "can we prevent an 18-year old with a first psychotic episode from sliding into chronic disease?" -we are soberingly far from possessing the understanding that we need to make a difference (Hyman, 2012; Insel, 2012) . The issue is not so much a shortage of targets for drug development, rather, perhaps, the lack of a strategy for approaching the basic biology of schizophrenia with an eye to 
